Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro

American Journal of Pathology

Volumn 187, Issue 6, 2017, Pages 1399-1412

  Nobuhara, Chloe K ^a   DeVos, Sarah L ^a   Commins, Caitlin ^a   Wegmann, Susanne ^a   Moore, Benjamin D ^a   Roe, Allyson D ^a   Costantino, Isabel ^a   Frosch, Matthew P ^a   Pitstick, Rose ^b   Carlson, George A ^b   Hock, Christoph ^c,d   Nitsch, Roger M ^c,d   Montrasio, Fabio ^c   Grimm, Jan ^c   Cheung, Anne E ^e   Dunah, Anthone W ^e   Wittmann, Marion ^e   Bussiere, Thierry ^e   Weinreb, Paul H ^e   Hyman, Bradley T ^a   Takeda, Shuko ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLAUGHLIN RESEARCH INSTITUTE   (United States)

^c Neurimmune Therapeutics AG   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN EXTRACT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 40E8; MONOCLONAL ANTIBODY 4E4; MONOCLONAL ANTIBODY 6C5; MONOCLONAL ANTIBODY HT7; MONOCLONAL ANTIBODY P396; MONOCLONAL ANTIBODY TAU13; MONOCLONAL ANTIBODY TAU46; TAU PROTEIN; UNCLASSIFIED DRUG; EPITOPE; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE;

ADULT; AGED; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERNEURON; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MOUSE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; UPTAKE ASSAY; VERY ELDERLY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN; CELL CULTURE; IMMUNOLOGY; METABOLISM; MICROFLUIDIC ANALYSIS; MOLECULARLY TARGETED THERAPY; NERVE CELL; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; TRANSGENIC MOUSE;

AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CELLS, CULTURED; EPITOPES; FEMALE; HUMANS; INTERNEURONS; MALE; MICE, TRANSGENIC; MICROFLUIDIC ANALYTICAL TECHNIQUES; MOLECULAR TARGETED THERAPY; NEUROFIBRILLARY TANGLES; NEURONS; PHOSPHORYLATION; TAU PROTEINS;

EID: 85019645401     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2017.01.022     Document Type: Article

References (35)

1. Mandelkow, E.M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., Mandelkow, E., Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging 16 (1995), 355–362 discussion 62–63.
2. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 (1991), 239–259.
3. Hyman, B.T., Van Hoesen, G.W., Damasio, A.R., Barnes, C.L., Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225 (1984), 1168–1170.
4. Takeda, S., Wegmann, S., Cho, H., DeVos, S.L., Commins, C., Roe, A.D., Nicholls, S.B., Carlson, G.A., Pitstick, R., Nobuhara, C.K., Costantino, I., Frosch, M.P., Muller, D.J., Irimia, D., Hyman, B.T., Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat Commun, 6, 2015, 8490.
5. de Calignon, A., Polydoro, M., Suarez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Pitstick, R., Sahara, N., Ashe, K.H., Carlson, G.A., Spires-Jones, T.L., Hyman, B.T., Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73 (2012), 685–697.
6. Liu, L., Drouet, V., Wu, J.W., Witter, M.P., Small, S.A., Clelland, C., Duff, K., Trans-synaptic spread of tau pathology in vivo. PLoS One, 7, 2012, e31302.
7. Harris, J.A., Koyama, A., Maeda, S., Ho, K., Devidze, N., Dubal, D.B., Yu, G.Q., Masliah, E., Mucke, L., Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One, 7, 2012, e45881.
8. Pedersen, J.T., Sigurdsson, E.M., Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21 (2015), 394–402.
9. Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E., Wozniak, D.F., Diamond, M.I., Holtzman, D.M., Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80 (2013), 402–414.
10. Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., Tomiyama, T., Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol 2 (2015), 241–255.
11. Collin, L., Bohrmann, B., Gopfert, U., Oroszlan-Szovik, K., Ozmen, L., Gruninger, F., Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 137 (2014), 2834–2846.
12. Chai, X., Wu, S., Murray, T.K., Kinley, R., Cella, C.V., Sims, H., Buckner, N., Hanmer, J., Davies, P., O'Neill, M.J., Hutton, M.L., Citron, M., Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286 (2011), 34457–34467.
13. d'Abramo, C., Acker, C.M., Jimenez, H., Davies, P., Passive immunization in JNPL3 transgenic mice using an array of phospho-tau specific antibodies. PLoS One, 10, 2015, e0135774.
14. Sankaranarayanan, S., Barten, D.M., Vana, L., Devidze, N., Yang, L., Cadelina, G., Hoque, N., DeCarr, L., Keenan, S., Lin, A., Cao, Y., Snyder, B., Zhang, B., Nitla, M., Hirschfeld, G., Barrezueta, N., Polson, C., Wes, P., Rangan, V.S., Cacace, A., Albright, C.F., Meredith, J. Jr., Trojanowski, J.Q., Lee, V.M., Brunden, K.R., Ahlijanian, M., Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One, 10, 2015, e0125614.
15. Boutajangout, A., Ingadottir, J., Davies, P., Sigurdsson, E.M., Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118 (2011), 658–667.
16. Castillo-Carranza, D.L., Sengupta, U., Guerrero-Munoz, M.J., Lasagna-Reeves, C.A., Gerson, J.E., Singh, G., Estes, D.M., Barrett, A.D., Dineley, K.T., Jackson, G.R., Kayed, R., Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34 (2014), 4260–4272.
17. Song, L., Lu, S.X., Ouyang, X., Melchor, J., Lee, J., Terracina, G., Wang, X., Hyde, L., Hess, J.F., Parker, E.M., Zhang, L., Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. Mol Neurodegener, 10, 2015, 14.
18. Barthelemy, N., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buee, L., Gabelle, A., Junot, C., Lehmann, S., Becher, F., Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res 15 (2016), 667–676.
19. Barten, D.M., Cadelina, G.W., Hoque, N., DeCarr, L.B., Guss, V.L., Yang, L., Sankaranarayanan, S., Wes, P.D., Flynn, M.E., Meredith, J.E., Ahlijanian, M.K., Albright, C.F., Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis 24 Suppl 2 (2011), 127–141.
20. Martin, L., Latypova, X., Terro, F., Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 58 (2011), 458–471.
21. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., Ashe, K.H., Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005), 476–481.
22. Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V., Montine, T.J., National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8 (2012), 1–13.
23. Goedert, M., Spillantini, M.G., Cairns, N.J., Crowther, R.A., Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8 (1992), 159–168.
24. Holmes, B.B., Furman, J.L., Mahan, T.E., Yamasaki, T.R., Mirbaha, H., Eades, W.C., Belaygorod, L., Cairns, N.J., Holtzman, D.M., Diamond, M.I., Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 111 (2014), E4376–E4385.
25. Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., Paul, S.M., Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep, 5, 2015, 11161.
26. Meredith, J.E. Jr., Sankaranarayanan, S., Guss, V., Lanzetti, A.J., Berisha, F., Neely, R.J., Slemmon, J.R., Portelius, E., Zetterberg, H., Blennow, K., Soares, H., Ahlijanian, M., Albright, C.F., Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS One, 8, 2013, e76523.
27. Pooler, A.M., Phillips, E.C., Lau, D.H., Noble, W., Hanger, D.P., Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14 (2013), 389–394.
28. Yamada, K., Cirrito, J.R., Stewart, F.R., Jiang, H., Finn, M.B., Holmes, B.B., Binder, L.I., Mandelkow, E.M., Diamond, M.I., Lee, V.M., Holtzman, D.M., In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31 (2011), 13110–13117.
29. Funk, K.E., Mirbaha, H., Jiang, H., Holtzman, D.M., Diamond, M.I., Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J Biol Chem 290 (2015), 21652–21662.
30. Congdon, E.E., Gu, J., Sait, H.B., Sigurdsson, E.M., Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 288 (2013), 35452–35465.
31. Krishnamurthy, P.K., Deng, Y., Sigurdsson, E.M., Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry, 2, 2011, 59.
32. Bi, M., Ittner, A., Ke, Y.D., Gotz, J., Ittner, L.M., Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One, 6, 2011, e26860.
33. Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., Rosenmann, H., Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224 (2010), 472–485.
34. Ittner, A., Bertz, J., Suh, L.S., Stevens, C.H., Gotz, J., Ittner, L.M., Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem 132 (2015), 135–145.
35. Serrano-Pozo, A., Frosch, M.P., Masliah, E., Hyman, B.T., Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med, 1, 2011, a006189.